Compare VINP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | PHAR |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | Brazil | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 793.4M |
| IPO Year | 2020 | 2020 |
| Metric | VINP | PHAR |
|---|---|---|
| Price | $9.26 | $10.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 40.8K | 33.8K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.07 | $10.04 |
| Revenue Next Year | $12.74 | $2.51 |
| P/E Ratio | ★ $24.41 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $9.62 |
| 52 Week High | $13.61 | $21.34 |
| Indicator | VINP | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 38.04 |
| Support Level | N/A | $9.62 |
| Resistance Level | $10.17 | $11.60 |
| Average True Range (ATR) | 0.26 | 0.47 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 14.94 | 9.45 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.